Physician profile
Lain L Lee
NPI 1538780218
$8,280.64
in general payments reported to CMS, 2019-2025
50 companies · $53.82 in 2025
The $53.82 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,809 · 2022: $3,843 · 2023: $2,521 · 2024: $53.49 · 2025: $53.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.84 |
| Education | $374.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $753.98 | 2021-2024 | |
| Pfizer INC. | $658.65 | 2021-2023 | |
| Astellas Pharma US INC | $559.15 | 2021-2023 | Padcev |
| Incyte Corporation | $509.03 | 2021-2023 | Jakafi |
| Eisai INC. | $398.70 | 2021-2023 | |
| Janssen Biotech, INC. | $377.17 | 2021-2023 | Imbruvica, Darzalex |
| Exelixis INC. | $330.39 | 2021-2023 | Cabometyx |
| Celgene Corporation | $327.77 | 2021-2023 | Pomalyst, Reblozyl |
| Merck Sharp & Dohme LLC | $321.56 | 2021-2023 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $318.14 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $313.13 | 2021-2023 | Ninlaro, Alunbrig |
| Seagen INC. | $282.64 | 2021-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $254.86 | 2021-2023 | Calquence, Lynparza |
| Amgen INC. | $252.23 | 2021-2023 | Lumakras |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.20 | 2021-2023 | Gilotrif |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $211.33 | 2021-2023 | Epkinly, Imbruvica |
| Gilead Sciences, INC. | $196.17 | 2021-2023 | Trodelvy |
| Karyopharm Therapeutics INC. | $191.86 | 2021-2022 | |
| Genzyme Corporation | $139.08 | 2022 | |
| Daiichi Sankyo INC. | $137.79 | 2021-2023 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $123.38 | 2021-2023 | Opdivo |
| Rigel Pharmaceuticals, INC. | $122.14 | 2021-2023 | Tavalisse, Rezlidhia |
| Lilly USA, LLC | $121.64 | 2021-2023 | Jaypirca, Verzenio |
| Sobi, INC | $113.02 | 2022-2023 | |
| Glaxosmithkline, LLC. | $107.69 | 2022-2023 | Zejula, Jemperli, Shingrix |
| Beigene USA, INC. | $95.98 | 2022-2023 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $88.27 | 2021-2023 | Onivyde, Somatuline Depot |
| Puma Biotechnology, INC. | $85.39 | 2022-2023 | |
| Abbvie INC. | $83.56 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $59.85 | 2021-2022 | |
| Taiho Oncology, INC. | $59.38 | 2021-2022 | |
| Eusa Pharma (US) LLC | $51.52 | 2021-2022 | |
| Genmab U.S., INC. | $41.67 | 2023 | Epkinly |
| Novocure INC. | $30.62 | 2022-2023 | Optune |
| Adaptive Biotechnologies Corporation | $27.45 | 2022 | |
| Emd Serono, INC. | $27.32 | 2021 | |
| Pharmaessentia USA Corporation | $23.95 | 2023 | Besremi |
| Jazz Pharmaceuticals INC. | $23.70 | 2022 | |
| Morphosys, US INC. | $22.53 | 2022 | |
| G1 Therapeutics, INC. | $22.25 | 2022 | |
| Stemline Therapeutics INC. | $21.52 | 2023 | Orserdu |
| Foundation Medicine, INC. | $20.96 | 2023 | Foundationone Liquid Cdx |
| Ge Healthcare | $20.33 | 2021 | |
| Deciphera Pharmaceuticals INC. | $19.31 | 2023 | Qinlock |
| Agios Pharmaceuticals, INC. | $19.26 | 2023 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $18.68 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $17.94 | 2021 | |
| Acrotech Biopharma INC. | $17.78 | 2022 | |
| Aveo Pharmaceuticals, INC. | $17.58 | 2022 | |
| Dova Pharmaceuticals | $15.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lain Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.